Q-omics provides the consensus-scored KDM2B profile across patient tissues and cancer cell-line models. KDM2B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KDM2B is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, KDM2B protein abundance shows 23,428 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight ACC, COAD, and HNSC as cancer lineages where KDM2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDM2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDM2B survival associations across molecular data types. KDM2B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDM2B RNA expression–survival associations across cancer types. High KDM2B expression shows unfavorable associations in ACC and KIRC, but favorable associations in HNSC, SCLC, BRCA and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KDM2B RNA expression.
This table summarizes KDM2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KDM2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDM2B shows lower tumor expression in THCA and higher tumor expression in COAD, KIRP, KIRC, BLCA and STAD. The COAD box plot shows higher KDM2B RNA expression in tumor versus normal tissue (log2 FC = +0.740, t-test p < 0.001).
This table shows molecular features associated with KDM2B in patient tissues and cancer cell lines. In patient samples, KDM2B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, KDM2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
